Found: 30
Select item for more details and to access through your institution.
West Nile Virus Central Nervous System Infection in Patients Treated With Rituximab: Implications for Diagnosis and Prognosis, With a Review of Literature.
- Published in:
- Open Forum Infectious Diseases, 2015, v. 2, n. 4, p. 1, doi. 10.1093/ofid/ofv136
- By:
- Publication type:
- Article
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01148-x
- By:
- Publication type:
- Article
Adoptively transferred TRAIL<sup>+</sup> T cells suppress GVHD and augment antitumor activity.
- Published in:
- Journal of Clinical Investigation, 2013, v. 123, n. 7, p. 2654, doi. 10.1172/JCI66301
- By:
- Publication type:
- Article
Adoptively transferred TRAIL<sup>+</sup> T cells suppress GVHD and augment antitumor activity.
- Published in:
- Journal of Clinical Investigation, 2013, v. 123, n. 6, p. 2654, doi. 10.1172/JCI66301
- By:
- Publication type:
- Article
Atrial arrhythmias following CAR‐chimeric antigen receptor T‐cell therapy: Incidence, risk factors and biomarker profile.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 3, p. 978, doi. 10.1111/bjh.19497
- By:
- Publication type:
- Article
Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 5, p. 774, doi. 10.1111/bjh.19037
- By:
- Publication type:
- Article
Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 1, p. 45, doi. 10.1111/bjh.16541
- By:
- Publication type:
- Article
The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 4, p. 650, doi. 10.1111/bjh.16424
- By:
- Publication type:
- Article
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 5, p. 735, doi. 10.1111/bjh.13897
- By:
- Publication type:
- Article
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 5, p. 709, doi. 10.1111/bjh.13883
- By:
- Publication type:
- Article
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 869, doi. 10.1007/s10637-018-0570-4
- By:
- Publication type:
- Article
Multidimensional Single-Cell Analysis of BCR Signaling Reveals Proximal Activation Defect As a Hallmark of Chronic Lymphocytic Leukemia B Cells.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0079987
- By:
- Publication type:
- Article
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
- Published in:
- European Heart Journal, 2023, v. 44, n. 22, p. 2029, doi. 10.1093/eurheartj/ehad117
- By:
- Publication type:
- Article
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
- Published in:
- Cancers, 2023, v. 15, n. 6, p. 1760, doi. 10.3390/cancers15061760
- By:
- Publication type:
- Article
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
- Published in:
- Therapeutic Advances in Hematology, 2016, v. 7, n. 4, p. 179, doi. 10.1177/2040620716654102
- By:
- Publication type:
- Article
Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1394057
- By:
- Publication type:
- Article
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e443, doi. 10.1016/j.clml.2021.12.010
- By:
- Publication type:
- Article
ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S378, doi. 10.1016/S2152-2650(21)01863-2
- By:
- Publication type:
- Article
Poster: ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S241, doi. 10.1016/S2152-2650(21)01513-5
- By:
- Publication type:
- Article
Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström's Macroglobulinemia (iNNOVATE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S283, doi. 10.1016/j.clml.2018.07.217
- By:
- Publication type:
- Article
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, n. 5, p. 687, doi. 10.1093/cid/ciy175
- By:
- Publication type:
- Article
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00620-w
- By:
- Publication type:
- Article
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 8, p. 1, doi. 10.1038/s41408-021-00539-8
- By:
- Publication type:
- Article
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00506-3
- By:
- Publication type:
- Article
Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 8, p. N.PAG, doi. 10.1038/s41408-020-00346-7
- By:
- Publication type:
- Article
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 7, p. N.PAG, doi. 10.1038/s41408-020-00340-z
- By:
- Publication type:
- Article
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41408-020-0277-6
- By:
- Publication type:
- Article
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0209-5
- By:
- Publication type:
- Article
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.
- Published in:
- EJHaem, 2024, v. 5, n. 5, p. 929, doi. 10.1002/jha2.1013
- By:
- Publication type:
- Article